Trilogy Capital Inc. Raises Position in Intuitive Surgical, Inc. $ISRG

Trilogy Capital Inc. increased its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 23.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,406 shares of the medical equipment provider’s stock after buying an additional 1,038 shares during the quarter. Trilogy Capital Inc.’s holdings in Intuitive Surgical were worth $2,418,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Intuitive Surgical by 2.1% during the second quarter. Vanguard Group Inc. now owns 33,335,833 shares of the medical equipment provider’s stock valued at $18,115,025,000 after purchasing an additional 670,302 shares during the period. State Street Corp grew its holdings in Intuitive Surgical by 1.2% during the 2nd quarter. State Street Corp now owns 15,552,203 shares of the medical equipment provider’s stock valued at $8,451,223,000 after purchasing an additional 182,871 shares in the last quarter. Geode Capital Management LLC increased its stake in Intuitive Surgical by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 8,188,685 shares of the medical equipment provider’s stock worth $4,429,590,000 after buying an additional 109,904 shares during the period. Norges Bank acquired a new position in Intuitive Surgical in the 2nd quarter worth $2,569,260,000. Finally, Invesco Ltd. boosted its position in Intuitive Surgical by 4.8% in the 2nd quarter. Invesco Ltd. now owns 4,421,133 shares of the medical equipment provider’s stock valued at $2,402,488,000 after buying an additional 201,159 shares during the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Intuitive Surgical

In related news, EVP Myriam Curet sold 104 shares of the business’s stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average price of $559.90, for a total transaction of $58,229.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Gary S. Guthart sold 22,806 shares of the company’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $570.89, for a total value of $13,019,717.34. Following the transaction, the insider owned 2,694 shares of the company’s stock, valued at approximately $1,537,977.66. The trade was a 89.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 114,007 shares of company stock worth $63,533,844. Corporate insiders own 0.70% of the company’s stock.

Intuitive Surgical Stock Performance

Intuitive Surgical stock opened at $586.24 on Monday. Intuitive Surgical, Inc. has a 1 year low of $425.00 and a 1 year high of $616.00. The firm’s 50-day moving average is $565.95 and its 200-day moving average is $511.38. The company has a market cap of $210.16 billion, a P/E ratio of 77.55, a PEG ratio of 4.77 and a beta of 1.67.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Tuesday, October 21st. The medical equipment provider reported $2.40 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.41. Intuitive Surgical had a net margin of 28.58% and a return on equity of 15.08%. The firm had revenue of $2.51 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same quarter in the prior year, the business earned $1.84 earnings per share. Intuitive Surgical’s quarterly revenue was up 22.9% on a year-over-year basis. As a group, sell-side analysts predict that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms recently commented on ISRG. Truist Financial boosted their price target on Intuitive Surgical from $620.00 to $650.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Hsbc Global Res raised Intuitive Surgical to a “strong-buy” rating in a research report on Thursday, October 23rd. Weiss Ratings reissued a “hold (c+)” rating on shares of Intuitive Surgical in a research report on Monday, December 29th. Rothschild & Co Redburn lifted their price target on shares of Intuitive Surgical from $610.00 to $615.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Finally, HSBC increased their price objective on shares of Intuitive Surgical from $595.00 to $644.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $622.17.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.